What is Nivolumab?

Nivolumab (Nivolumab) is an oncology drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, advanced renal cell carcinoma (RCC), classic Hodgkin lymphoma, squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), and esophageal cancer. Depending on the indication, it can be used as a single agent or in combination with ipilimumab, an anti-CTL4 immune checkpoint inhibitor.

Nivolumab is an immune checkpoint inhibitor (ICI), a monoclonal antibody targeting the anti-PD1 receptor (an immune checkpoint). Nivolumab is administered as a 30-minute intravenous infusion, and the most common dosage regimen is 240 mg every two weeks or 480 mg every four weeks, depending on the indication. Nivolumab can be diluted with 9 mg/mL (0.9%) sodium chloride solution or 50 mg/mL (5%) glucose solution for injection. Regardless of the diluent used, it is recommended to use it immediately after preparation of the solution.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.